Lin CY - Search Results

1

2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population.

Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Lin HC, Kao JH, Chuang WL. Yu ML, et al. Among authors: lin cy, lin hc. J Formos Med Assoc. 2020 Jun;119(6):1019-1040. doi: 10.1016/j.jfma.2020.04.003. Epub 2020 Apr 29. J Formos Med Assoc. 2020. PMID: 32359879 Free article. Review.

2

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.

Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS. Lin CY, et al. Among authors: lin tn. PLoS One. 2011 Mar 30;6(3):e18322. doi: 10.1371/journal.pone.0018322. PLoS One. 2011. PMID: 21479134 Free PMC article.

3

None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.

Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. Jeng WJ, et al. Among authors: lin cy. PLoS One. 2012;7(11):e48217. doi: 10.1371/journal.pone.0048217. Epub 2012 Nov 16. PLoS One. 2012. PMID: 23173032 Free PMC article.

4

Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism.

Lin CY, Sheen IS, Jeng WJ, Huang CW, Huang CH, Chen JY. Lin CY, et al. Ann Hepatol. 2013 Jan-Feb;12(1):62-9. Ann Hepatol. 2013. PMID: 23293195 Free article.

5

Various predictors of sustained virologic response in different age groups of patients with genotype-1 chronic hepatitis C.

Lin CY, Sheen IS, Chen JY, Huang CW, Huang CH, Jeng WJ, Chen WT. Lin CY, et al. J Clin Gastroenterol. 2013 Oct;47(9):794-9. doi: 10.1097/MCG.0b013e31829d2064. J Clin Gastroenterol. 2013. PMID: 23842218

6

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.

Lee MH, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, Yu ML, Chuang WL, Chen CJ. Lee MH, et al. Among authors: lin cy. Sci Rep. 2017 Jun 16;7(1):3718. doi: 10.1038/s41598-017-02313-y. Sci Rep. 2017. PMID: 28623331 Free PMC article.

7

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.

Hsieh YC, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin SM, Tai DI, Lin CY, Sheen IS. Hsieh YC, et al. Among authors: lin cy, lin sm. PLoS One. 2018 Aug 23;13(8):e0202777. doi: 10.1371/journal.pone.0202777. eCollection 2018. PLoS One. 2018. PMID: 30138456 Free PMC article.

8

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.

Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Yu ML, et al. Among authors: lin cy. J Formos Med Assoc. 2019 Feb;118(2):556-564. doi: 10.1016/j.jfma.2018.11.007. Epub 2018 Dec 5. J Formos Med Assoc. 2019. PMID: 30527566 Free article. Clinical Trial.

9

Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients.

Chen YC, Teng W, Hsieh YC, Chen WT, Jeng WJ, Huang CH, Lin CC, Chen YC, Lin SM, Lin CY, Sheen IS. Chen YC, et al. Among authors: lin cy, lin cc, lin sm. J Formos Med Assoc. 2019 Aug;118(8):1239-1246. doi: 10.1016/j.jfma.2018.11.014. Epub 2018 Dec 21. J Formos Med Assoc. 2019. PMID: 30581103 Free article.

10

An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.

Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, Yu ML. Huang CF, et al. Among authors: lin cy. J Infect Dis. 2019 Jul 19;220(4):557-566. doi: 10.1093/infdis/jiz154. J Infect Dis. 2019. PMID: 30957170 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,400 results

Search Page